Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing organization (CDMO) that regularly issues news on its operations, financial performance, and corporate developments. The company focuses on serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets, and its updates reflect activity across these areas.
On this page, readers can follow ITGR news related to quarterly earnings, product line performance, and outlooks that Integer provides through press releases furnished with Form 8-K filings. These releases often include discussions of sales trends in Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, along with non-GAAP financial measures such as adjusted operating income, adjusted EBITDA, adjusted net income, and adjusted earnings per share.
Integer’s news flow also covers strategic and governance events, such as leadership transitions, board appointments, and capital allocation decisions. Recent examples include the appointment of a new President and Chief Executive Officer, the election of a new director with extensive medical device industry experience, and the authorization of a share repurchase program by the Board of Directors.
In addition, Integer publishes updates on technology and market-facing activities, such as participation in medical society meetings and healthcare investor conferences. The company has highlighted innovations in neuromodulation and miniaturized active implantable medical devices, including high-performance batteries and integrated implantable pulse generator and lead systems, as well as its Xcellion Gen 3 fast charge lithium ion battery technology.
Investors and observers can use this news page to monitor how Integer communicates its strategy, product line dynamics, financing actions, and role as a CDMO in the cardiac rhythm management, neuromodulation, and cardio and vascular markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Integer Holdings Corporation (NYSE:ITGR) reported a strong performance in Q1 2023, with sales increasing 22% to $379 million and organic growth of 21%. GAAP net income rose by $2 million to $13 million, while non-GAAP adjusted net income grew by $3 million to $29 million. GAAP operating income surged 52% to $34 million, and adjusted operating income increased 28% to $50 million. Adjusted EBITDA also saw a 22% rise to $66 million. However, total debt increased by $77 million, reaching $1,002 million, resulting in a leverage ratio of 3.6 times adjusted EBITDA. The company anticipates organic sales growth of 7% to 9% for the full year 2023, with continued margin expansion expected.
Integer Holdings Corporation (NYSE:ITGR) will release its first quarter 2023 financial results on April 27, 2023, at 7 a.m. CT / 8 a.m. ET. Following the earnings release, a conference call will be held at 8 a.m. CT / 9 a.m. ET to discuss the results and any material forward-looking information. Investors can access the call via domestic or international dial-in numbers, with a conference ID of 9252310. Audio replay will be available for seven days. Integer is a leading medical device outsourcing manufacturer, providing innovative technologies across multiple markets.
Integer Holdings Corporation (NYSE:ITGR) will participate in a virtual fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 10:30 AM ET. The chat will feature Joe Dziedzic, President and CEO, and Jason Garland, CFO. Interested investors can access the live and archived webcast via the company’s investor relations website. Integer is a leading medical device outsourcing manufacturer, serving various markets including cardiac and orthopedics.